重新思考免疫检查点抑制在癌症中的抑制
Tibor Bakacs1,2, Colin C Anderson3
1HUN-REN Alfréd Rényi Institute of Mathematics, Budapest, Hungary.
Scandinavian journal of immunology
|March 11, 2026
概括
免疫检查点抑制剂 (ICI) 可以引起与免疫相关的不良事件 (irAEs). 通过慢性移植与宿主疾病 (cGVHD) 镜头观察ICI诱导的自身免疫,可以指导更安全的剂量策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 移植 移植 移植 移植
背景情况:
- 免疫检查点抑制剂 (ICI) 为一些患者提供持久的癌症治疗.
- 对ICI的一个重大挑战是免疫相关不良事件 (irAEs) 的发展,这些不良事件可能是严重的,并且没有临床益处.
- 传统的自我耐受模式不能完全解释ICI诱导的自身免疫.
研究的目的:
- 探索一种新的框架来理解ICI诱导的自身免疫.
- 调查iRAE与慢性移植与宿主疾病 (cGVHD) 之间的相似之处.
- 确定潜在的策略,以减轻ICI毒性.
主要方法:
- 对cGVHD和ICI诱导的irAEs进行比较的转录基因分析.
- 对使用超低剂量ICI疗程的临床经验的回顾.
主要成果:
- ICI诱导的irAEs与cGVHD共享一个共同的分子生态系统,其特征是干扰素条件下的组织状态.
- 超低剂量ICI疗法显示,可以保持抗瘤活性,同时显著降低毒性.
结论:
- 一个类似cGVHD的模型为ICI诱导的自身免疫性背后的机制提供了新的视角.
- 这一框架可以为开发更安全的ICI剂量策略提供信息.
- 了解这些相似之处可以在全球范围内扩大对免疫治疗的准入.
更多相关视频
09:04Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
1.8K
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.6K
相关概念视频
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Inhibition of CDK Activity
5.6K
5.6K
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
The Intrinsic Apoptotic Pathway
9.0K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
Mitogens and the Cell Cycle
8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
